One-pot Fluorination and Organocatalytic Robinson Annulation for Asymmetric Synthesis of Mono- and Difluorinated Cyclohexenones

Xin Huang ^{1,*} Weizhao Zhao ¹, Xiaofeng Zhang ², Miao Liu ², Stanley N.S. Vasconcelos ³ and Wei Zhang ^{2,*}

1 College of Chemistry and Life Sciences, Zhejiang Normal University, Jinhua 321004, China; zhao792129582@163.com

2 Department of Chemistry, University of Massachusetts Boston, 100 Morrissey Boulevard, Boston, MA 02125, USA; Xiaofeng.Zhang002@umb.edu (X.Z.); liumiaomarcus@gmail.com (M.L.)

3 Departamento de Farmácia, Universidade de São Paulo, Av. Prof. Lineu Prestes, 580 São Paulo, SP 05508-000, Brasil; stanleynsv@gmail.com

* Correspondence: xin.huang@zjnu.cn (X.H.); wei2.zhang@umb.edu (W.Z.); Tel.: +1-617-287-6147 (W.Z.); Fax: +1-617-287-6030 (W.Z.)

Contents

1.	General Information	S2
2.	Analytical Data of Products	S3
3.	NMR Spectra of Products	S7
4.	Chiral-LC of Products	S27

1. General Information

Chemicals and solvents were purchased from commercial suppliers and used as received. ¹H and ¹³C NMR spectra were recorded on a 400 MHz Agilent NMR spectrometer. Chemical shifts were reported in parts per million (ppm), and the residual solvent peak was used as an internal reference: proton (chloroform δ 7.26), carbon (chloroform δ 77.0). Multiplicity was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), br s (broad singlet). Coupling constants were reported in Hertz (Hz). LC-MS were performed on an Agilent 2100 system. A C₁₈ column (5.0 µm, 6.0 x 50 mm) was used for the separation. The mobile phases were methanol and water both containing 0.05% trifluoro acetic acid. A linear gradient was used to increase from 25:75 v/v methanol/water to 100% methanol over 7.0 min at a flow rate of 0.7 mL/min. UV detections were conducted at 210 nm, 254 nm and 365 nm. Low resolution mass spectra were recorded in APCI (atmospheric pressure chemical ionization). The high resolution mass spectra were obtained on a Waters Micromass GCT Premier. Sorbent silica gel XHL TLC plates (130815) were used for the thin-layer chromatography (TLC). Flash chromatography separations were performed on YAMAZEN AI-580 flash column system with Agela silica gel columns (230-400 µm mesh) and Angela Flash/Cheeta System with Venusil PrepG C₁₈ column (10 µm, 120 Å, 21.2 mm x 250 mm). The enantiomeric excesses of products were determined by chiral phase HPLC analysis on a SHIMADZU LC-20AD system with Venusil Chiral CA, CD-H, and Regis (R,R)-Whelk-O1 column.

1.1 General procedure for Asymmetric Synthesis of Fluorinated Cyclohexanones:

To a solution of β -ketoesters **8** (0.1 mmol) in CH₃CN (0.5 mL) was added SelectfluorTM (0.15 mmol). After being stirred and heated at 120 °C in microwave reaction station for 20 min, the reaction mixture was allowed to cool to room temperature and then **cat-1** (7 mg, 0.02 mmol), CF₃C₆H₄COOH (4 mg, 0.02 mmol) and α,β -unsaturated ketones **6** (0.15 mmol) were added. The reaction mixture was stirred for 30 min before the addition of Na₂CO₃ (16 mg, 1.5 equiv.) After being stirred for 48 h, the resulting fluorinated cyclohexenones **3-4** were purified by YAMAZEN AI-580 flash column system with Agela silica gel columns (hexanes/ethyl acetate as eluent).

2. Analytical Data of Products

G CO2Et

The enantiomeric excess was determined by HPLC analysis (Venusil Chiral CD column, 90:10 hexane/i-PrOH, 1.0 mL/min, $\lambda = 254$ nm): tminor = 12.15 min, tmajor = 9.38 min, 99% ee.

¹H NMR (400 MHz, cdcl₃) δ 7.72 – 7.54 (m, 2H), 7.50 – 7.42 (m, 3H), 7.41 – 7.31 (m, 5H), 6.63 (dd, *J* = 2.9, 2.2 Hz, 1H), 4.15 (q, *J* = 7.1 Hz, 2H), 3.90 – 3.74 (m, 2H), 3.23 – 3.10 (m, 1H), 1.13 (t, *J* = 7.1 Hz, 3H).

 ^{19}F NMR (376 MHz, cdcl₃) δ -165.47.

¹³C NMR (101 MHz, cdcl₃) δ 189.86 (d, J = 17.7 Hz), 165.61 (d, J = 26.3 Hz), 161.33, 137.42, 136.12, 130.94, 128.99, 128.69, 128.50, 128.36, 126.35, 122.61, 95.05 (d, J = 204.0 Hz), 62.3, 48.81 (d, J = 21.2 Hz), 32.64 (d, J = 4.0 Hz), 13.87.

HRMS (EI, m/z): calcd. for C₂₁H₁₉FO₃ [M]⁺: 338.1318, Found: 338.1321.



The enantiomeric excess was determined by HPLC analysis (Venusil Chiral CD column, 95:5 hexane/*i*-PrOH, 1.0 mL/min, $\lambda = 254$ nm): tminor = 14.58 min, tmajor = 11.55 min, 99% ee.

3b Br ¹H NMR (400 MHz, cdcl₃) δ 7.65 – 7.56 (m, 2H), 7.54 – 7.40 (m, 5H), 7.22 (d, *J* = 8.3 Hz, 2H), 6.62 (dd, *J* = 2.9, 2.1 Hz, 1H), 4.15 (q, *J* = 7.1 Hz, 2H), 3.88 – 3.71 (m, 2H), 3.20 – 3.06 (m, 1H), 1.16 (t, *J* = 7.1 Hz, 3H).

 ^{19}F NMR (376 MHz, cdcl₃) δ -165.24.

¹³C NMR (101 MHz, cdcl₃) δ 189.42 (d, J = 17.2 Hz), 165.41 (d, J = 27.3 Hz), 161.01, 137.28, 135.08, 131.82, 131.02, 130.18, 129.01, 128.36, 126.32, 122.59, 94.72 (d, J = 204.0 Hz), 62.50, 48.21 (d, J = 21.2 Hz), 32.41 (d, J = 8.1 Hz), 13.90.

HRMS (EI, m/z): calcd. for C₂₁H₁₈BrFO₃ [M]⁺: 416.0423, Found: 416.0426.



The enantiomeric excess was determined by HPLC analysis (Venusil Chiral CD column, 95:5 hexane/*i*-PrOH, 1.0 mL/min, $\lambda = 254$ nm): tminor = 15.34 min, tmajor = 16.24 min, 96% ee.

^{3c} CH₃ ¹H NMR (400 MHz, cdcl₃) δ 7.62 – 7.56 (m, 2H), 7.44 (qdd, *J* = 5.6, 3.6, 1.6 Hz, 3H), 7.30 (dd, *J* = 8.1, 1.2 Hz, 2H), 7.15 (dd, *J* = 8.3, 0.6 Hz, 2H), 6.61 (d, *J* = 2.0 Hz, 1H), 4.16 (q, *J* = 7.1, 2H), 4.00 – 3.80 (m, 1H), 3.35 (ddd, *J* = 18.3, 10.9, 2.4 Hz, 1H), 3.04 (dd, *J* = 18.3, 4.7 Hz, 1H), 2.34 (s, 3H), 1.13 (t, *J* = 7.1 Hz, 3H).

¹⁹F NMR (376 MHz, cdcl₃) δ -175.16.

¹³C NMR (101 MHz, cdcl₃) δ 188.58 (d, *J* = 17.2 Hz), 166.56 (d, J = 26.2 Hz), 161.24, 137.94, 137.43, 133.84, 130.92, 129.40, 128.97, 128.55 (d, J = 2.5 Hz), 126.30, 121.99, 94.59 (d, J = 197.2 Hz), 61.90, 47.24 (d, J = 22.0 Hz), 32.00 (d, J = 5.6 Hz), 21.09, 13.96.

HRMS (EI, m/z): calcd. for C₂₂H₂₁FO₃ [M]⁺: 352.1475, Found: 352.1477.



The enantiomeric excess was determined by HPLC analysis (Venusil Chiral CD column, 95:5 hexane/*i*-PrOH, 1.0 mL/min, $\lambda = 254$ nm): tminor = 9.05 min, tmajor = 7.11 min, 97% ee.

3d SMe ¹H NMR (400 MHz, cdcl₃) δ 7.65 - 7.58 (m, 2H), 7.50 - 7.40 (m, 3H), 7.25 (s, 4H), 6.62 (dd, J = 2.9, 2.1 Hz, 1H), 4.16 (q, J = 7.2 Hz, 2H), 3.93 - 3.65 (m, 2H), 3.14 (ddt, J = 16.7, 13.8, 7.1 Hz, 1H), 2.49 (s, 3H), 1.15 (t, J = 7.1 Hz, 3H).
¹⁹F NMR (376 MHz, cdcl₃) δ -165.53.

¹³C NMR (101 MHz, cdcl₃) δ 188.76 (d, J = 18.2 Hz), 166.54 (d, J = 26.3 Hz), 161.24, 138.87, 137.40, 132.76, 130.94, 128.98, 128.90, 126.58, 126.27, 122.60, 95.01 (d, J = 204.0 Hz), 62.39, 48.32 (d, J = 22.2 Hz), 32.63 (d, J = 8.1 Hz), 15.65, 13.91.

HRMS (EI, m/z): calcd. for $C_{22}H_{21}FO_3S$ [M]⁺: 384.1195, Found: 384.1196.



The enantiomeric excess was determined by HPLC analysis (Venusil Chiral CA column, 90:10 hexane/*i*-PrOH, 1.0 mL/min, $\lambda = 254$ nm): tminor = 15.57 min, tmajor = 10.60 min, 93% ee.

¹H NMR (400 MHz, cdcl₃) δ 7.67 – 7.55 (m, 6H), 7.52 – 7.40 (m, 7H), 7.36 (dt, J = 9.4, 4.3 Hz, 1H), 6.64 (d, J = 2.1 Hz, 1H), 4.18 (q, J = 7.1, 2H), 4.00 (ddd,

J = 35.8, 10.9, 4.7 Hz, 1H), 3.41 (ddd, *J* = 18.3, 11.0, 2.4 Hz, 1H), 3.10 (dd, *J* = 18.3, 4.7 Hz, 1H), 1.13 (t, *J* = 7.1 Hz, 3H).

¹⁹F NMR (376 MHz, cdcl₃) δ -175.02.

¹³C NMR (101 MHz, cdcl₃) δ 188.42 (d, J = 20.2 Hz), 166.7, 161.13, 140.45, 137.37, 130.98, 129.14, 129.12, 129.00, 128.80, 127.47, 127.41, 127.06, 127.03, 126.32, 122.02, 94.49 (d, J = 197.0 Hz), 62.02, 47.30 (d, J = 22.2 Hz), 31.92 (d, J = 6.1 Hz), 13.91.

HRMS (EI, m/z): calcd. for C₂₇H₂₃FO₃ [M]⁺: 414.1631, Found: 414.1633.



The enantiomeric excess was determined by HPLC analysis (Venusil Chiral CA column, 90:10 hexane/*i*-PrOH, 1.0 mL/min, $\lambda = 254$ nm): tminor = 19.43 min, tmajor = 13.77 min, 99% ee.

¹H NMR (400 MHz, cdcl₃) δ 7.67 – 7.52 (m, 6H), 7.53 – 7.39 (m, 3H), 6.63 (d, J = 2.1 Hz, 1H), 4.17 (q, J = 7.1, 2H), 4.11 – 3.96 (m, 1H), 3.37 (ddd, J =

18.2, 11.0, 2.4 Hz, 1H), 3.07 (dd, *J* = 18.2, 4.8 Hz, 1H), 1.11 (t, *J* = 7.1 Hz, 3H).

¹⁹F NMR (376 MHz, cdcl₃) δ -62.76, -174.96.

¹³C NMR (101 MHz, cdcl₃) δ 187.82 (d, J = 20.2 Hz), 166.29 (d, J = 26.3 Hz), 160.67, 140.85, 137.12, 131.13, 130.36, 129.15 (d, J = 3.0 Hz), 129.06, 126.29, 125.71 (q, J = 3.7 Hz), 122.54, 94.00 (d, J = 198.0 Hz), 62.19, 47.31 (d, J = 22.2 Hz), 31.66 (d, J = 6.1 Hz), 13.91.

HRMS (EI, m/z): calcd. for C₂₂H₁₈F₄O₃ [M]⁺: 406.1192, Found: 406.1192.



The enantiomeric excess was determined by HPLC analysis (Venusil Chiral CD column, 95:5 hexane/*i*-PrOH, 1.0 mL/min, $\lambda = 254$ nm): tminor = 3.25 min, tmajor = 3.73 min, 93% ee.

3g OMe ¹H NMR (400 MHz, cdcl₃) δ 7.63 – 7.55 (m, 2H), 7.51 – 7.39 (m, 3H), 7.10 – 6.99 (m, 2H), 6.95 – 6.90 (m, 1H), 6.61 (d, J = 2.0 Hz, 1H), 4.18 (q, J = 7.2 Hz, 2H), 4.02 – 3.81 (m, 4H), 3.32 (ddd, J = 18.2, 11.0, 2.4 Hz, 1H), 3.06 (dd, J = 18.2, 4.7 Hz, 1H), 1.14 (t, J = 7.1 Hz, 3H). ¹⁹F NMR (376 MHz, cdcl₃) δ -135.60, -175.19.

¹³C NMR (101 MHz, cdcl₃) δ 188.20 (d, J = 20.2 Hz), 166.47 (d, J = 27.3 Hz), 160.93 (s), 152.2 (d, J = 248.5 Hz), 147.63 (d, J = 10.8 Hz), 137.24, 133.30 (d, J = 3.6 Hz), 132.82, 131.05, 129.02, 128.55 (d, J = 16.6 Hz), 126.31, 121.98, 121.22 (d, J = 7.0 Hz), 116.13 (d, J = 18.4 Hz), 113.86, 94.40 (d, J = 198.0 Hz), 62.05, 56.30, 47.19, 3(d, J = 22.2 Hz), 2.09 (d, J = 5.4 Hz), 14.01.

HRMS (EI, m/z): calcd. for C₂₂H₂₀F₂O₃ [M]⁺: 386.1330, Found: 386.1342.



The enantiomeric excess was determined by HPLC analysis (Venusil Chiral CD column, 95:5 hexane/*i*-PrOH, 1.0 mL/min, $\lambda = 254$ nm): tminor = 18.64 min, tmajor = 14.40 min, 96% ee.

¹H NMR (400 MHz, cdcl₃) δ 7.68 – 7.56 (m, 2H), 7.52 – 7.41 (m, 3H), 7.28 (dd, J = 5.1, 1.2 Hz, 1H), 7.10 (ddd, J = 3.5, 2.0, 0.9 Hz, 1H), 7.03 (dd, J = 5.1, 3.6 Hz,

1H), 6.66 – 6.58 (m, 1H), 4.25 – 4.06 (m, 3H), 3.75 (ddd, *J* = 18.0, 11.7, 2.5 Hz, 1H), 3.32 (ddd, *J* = 18.0, 5.2, 2.4 Hz, 1H), 1.15 (t, *J* = 7.1 Hz, 3H).

¹⁹F NMR (376 MHz, cdcl₃) δ -163.76.

¹³C NMR (101 MHz, cdcl₃) δ 189.28 (d, J = 17.7 Hz), 165.24, 160.58, 138.63, 137.23, 131.01, 129.02, 127.01, 126.76, 126.34, 125.10, 122.67, 94.63 (d, J = 203.0 Hz), 62.50, 44.10 (d, J = 22.2 Hz), 34.02 (d, J = 7.7 Hz), 13.83.

HRMS (EI, m/z): calcd. for $C_{19}H_{17}FO_3S [M]^+$: 344.0882, Found: 344.0990.



The enantiomeric excess was determined by HPLC analysis (Venusil Chiral CD column, 95:5 hexane/*i*-PrOH, 1.0 mL/min, $\lambda = 254$ nm): tminor = 24.75 min, tmajor = 12.14 min, 89% ee.

¹H NMR (400 MHz, cdcl₃) δ 7.63 – 7.53 (m, 2H), 7.41 (dt, J = 8.0, 1.4 Hz, 2H), 7.39 – 7.28 (m, 3H), 7.01 – 6.89 (m, 2H), 6.58 (d, J = 2.0 Hz, 1H), 4.14

(dq, *J* = 7.1, 3.5 Hz, 2H), 4.02 – 3.79 (m, 4H), 3.32 (ddd, *J* = 18.1, 11.0, 2.3 Hz, 1H), 3.06 (dd, *J* = 18.1, 4.8 Hz, 1H), 1.09 (t, *J* = 7.1 Hz, 3H).

 19 F NMR (376 MHz, cdcl₃) δ -174.75.

¹³C NMR (101 MHz, cdcl₃) δ 188.38 (d, J = 20.2 Hz), 166.72 (d, J = 25.4 Hz), 162.06, 160.42, 137.02, 129.33, 128.75, 128.72, 128.17, 128.03, 120.00, 114.39, 94.51 (d, J = 196.0 Hz), 61.87, 55.45, 47.54(d, J = 22.2 Hz), 31.57 (d, J = 5.4 Hz), 13.93.

HRMS (EI, m/z): calcd. for $C_{22}H_{21}FO_4$ [M]⁺: 368.1424, Found: 368.1421.



The enantiomeric excess was determined by HPLC analysis (Venusil Chiral CD column, 95:5 hexane/*i*-PrOH, 1.0 mL/min, $\lambda = 254$ nm): tminor = 15.74 min, tmajor = 14.36 min,85% ee.

¹H NMR (400 MHz, cdcl₃) δ 8.28 – 8.16 (m, 2H), 7.67 – 7.55 (m, 4H), 7.53 – 7.39 (m, 3H), 6.64 (d, J = 2.0 Hz, 1H), 4.23 – 4.02 (m, 3H), 3.37 (ddd, J =

18.1, 11.0, 2.4 Hz, 1H), 3.08 (dd, *J* = 18.1, 4.8 Hz, 1H), 1.14 (t, *J* = 7.1 Hz, 3H). ¹⁹F NMR (376 MHz, cdcl₃) δ -174.84.

¹³C NMR (101 MHz, cdcl₃) δ 187.43 (d, J = 20.2 Hz), 166.12 (d, J = 25.3 Hz), 160.40, 147.79, 144.06, 136.96, 131.25, 129.77 (d, J = 2.9 Hz), 129.11, 126.29, 123.95, 122.02, 93.73 (d, J = 197.0 Hz), 62.36, 47.19 (d, J = 21.2 Hz), 31.49 (d, J = 5.2 Hz), 14.00.

HRMS (EI, m/z): calcd. for C₂₁H₁₈FNO₅ [M]⁺: 383.1169, Found383.1167.



The enantiomeric excess was determined by HPLC analysis (Venusil Chiral CD column, 90:10 hexane/*i*-PrOH, 1.0 mL/min, $\lambda = 254$ nm): tminor = 16.54 min, tmajor = 14.48 min, 93% ee.

¹H NMR (400 MHz, cdcl₃) δ 7.63 – 7.55 (m, 2H), 7.52 (ddd, J = 4.0, 3.4, 1.6 Hz, 2H), 7.49 – 7.41 (m, 2H), 7.34 – 7.28 (m, 2H), 7.27 – 7.24 (m, 2H), 6.48 (d, J =

4.3 Hz, 1H), 5.92 (ddd, *J* = 11.4, 9.4, 1.5 Hz, 1H), 5.22 (ddd, *J* = 47.6, 12.8, 0.8 Hz, 1H), 3.94 – 3.70 (m, 1H).

 ^{19}F NMR (376 MHz, cdcl₃) δ -177.97, -196.93.

¹³C NMR (101 MHz, cdcl₃) δ 202.07, 191.22, 156.95, 133.80, 132.66, 132.26, 130.98, 129.79, 128.93, 127.37, 127.35, 124.44, 122.51, 90.70, 89.99, 79.02, 77.30, 77.18, 76.98, 76.66, 63.70, 53.41.
HRMS (ESI, m/z): calcd. for C₁₈H₁₄F₂ONa [M+Na]⁺: 307.0910, Found: 307.0910.



The enantiomeric excess was determined by HPLC analysis (Venusil Chiral CD column, 90:10 hexane/*i*-PrOH, 1.0 mL/min, $\lambda = 254$ nm): tminor = 12.53 min, tmajor = 9.39 min, 89% ee.

¹H NMR (400 MHz, cdcl₃) δ 7.58 – 7.49 (m, 2H), 7.50 – 7.32 (m, 7H), 6.48 (d, J = 4.3 Hz, 1H), 5.97 (ddd, J = 46.8, 9.3, 1.6 Hz, 1H), 5.26 (ddd, J = 47.6, 12.8,

0.8 Hz, 1H), 3.98 – 3.68 (m, 1H).

 ^{19}F NMR (376 MHz, cdcl₃) δ -177.60, -196.92.

HRMS (EI, m/z): calcd. for C₁₈H₁₃BrF₂O [M]⁺: 362.0118, Found: 362.0127.



The enantiomeric excess was determined by HPLC analysis (Venusil Chiral CD column, 90:10 hexane/*i*-PrOH, 1.0 mL/min, $\lambda = 254$ nm): tminor = 28.12 min, tmajor = 20.48 min, 93% ee.

¹H NMR (400 MHz, cdcl₃) δ 8.71 (d, J = 5.8 Hz, 2H), 7.52 (ddt, J = 6.1, 4.3, 2.0 Hz, 2H), 7.50 – 7.42 (m, 2H), 7.37 (d, J = 6.0 Hz, 2H), 7.27 – 7.25 (m, 1H), 6.50

(d, *J* = 4.4 Hz, 1H), 5.97 (ddd, *J* = 47.0, 9.4, 1.6 Hz, 1H), 5.26 (ddd, *J* = 47.7, 12.9, 0.8 Hz, 1H), 3.99 – 3.67 (m, 1H).

¹⁹F NMR (376 MHz, cdcl₃) δ -177.98, -196.91.

¹³C NMR (101 MHz, cdcl₃) δ 176.46, 150.50, 143.73, 131.11, 128.99, 127.36, 127.34, 124.45, 123.35, 89.49, 87.70, 77.30, 76.98, 76.66, 53.19, 39.15, 38.29.

HRMS (EI, m/z): calcd. for C₁₇H₁₃F₂NO [M]⁺: 285.0965, Found: 285.0963.

3. NMR Spectra of Products









Xin-RB-Br-3



30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 fl (ppm)







30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 f1 (ppm)







30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 f1 (ppm)











30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 f1 (ppm)









30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 f1 (ppm)





FLUORINE_01 STANDARD FLUORINE PARAMETERS




4. Chiral LC of Products



Racemic sample



Retention	Area %	Height %
6.268	5.80	9.54
7.136	0.38	0.57
9.376	93.28	89.35
12.152	0.55	0.54
Totals	100.00	100.00



Racemic sample

Retention	Area %	Height %
11.552	33.19	45.82
14.588	33.00	26.23
17.700	16.99	17.34



Enantioenriched sample

	Retention	Area %	Height %
_	11.743	100.00	10.00
	Totals	100.00	100.00
300 - 200			
CO_2Et F $3c$ CH_3 Racemic same	ple		

Retention	Area %	Height %
15.096	39.39	45.80
16.228	41.84	38.98
20.436	9.48	7.86
22.988	9.29	7.36
Totals	100.00	100.00



Enantioenriched sample

Retention	Area %	Height %
15.340	1.92	2.96



Racemic sample

3d

SMe

Retention	Area %	Height %
5.408	11.61	16.22
6.388	11.27	12.83
7.144	38.65	39.87
9.024	38.48	31.07
Totals	100.00	100.00



Enantioenriched sample



Retention	Area %	Height %
10.604	96.52	97.31
15.576	3.48	2.69
Totals	100.00	100.00



CF₃

F

3f

Retention	Area %	Height %
13.772	50.91	55.65
19.428	49.09	44.35
Totals	100.00	100.00
 500		



Enantioer	riched	samp	le
Linamitoer	nicheu	samp	IC.

ş

Retention	Area %	Height %
13.968	100.00	100.00
Totals	100.00	100.00





2000

₹ 1000

Racemic sample

	Retention	Area %	Height %
	3.212	33.35	39.53
	3.504	33.89	34.83
	4.840	16.40	13.45
	5.696	16.35	12.19
	Totals	100.00	100.00
3.21 83.3 5.00 339.9 6.4 4	-2000 		
	0		

Enantioenriched sample

		Retention	Area %	Height %
		3.252	3.46	4.30
		3.732	96.54	95.70
		Totals	100.00	100.00
00	1500			
00 -	- 1000			
		R.		





15

Racemic sample

Retention	Area %	Height %
14.764	7.48	12.71
16.696	42.26	55.03
18.480	7.77	9.85
32.668	42.48	22.41
Totals	100.00	100.00



Enantioenriched sample

Retention	Area %	Height %
14.402 (major)	90.62	93.22
17.293 (minor)	3.88	3.83
18.649 (major)	1.21	1.12
34.490 (minor)	4.19	1.83
Totals	100.00	100.00







Retention	Area %	Height %
12.144	94.62	96.17
24.756	5.38	3.83
Totals	100.00	100.00



Racemic sample

Retention	Area %	Height %
14.196	49.56	49.90
15.392	50.44	50.10
Totals	100.00	100.00



Retention	Area %	Height %
14.368	92.42	91.57
15.740	7.58	8.43
Totals	100.00	100.00













_	Retention	Area %	Height %
_	9.392	94.28	93.10
	12.536	5.72	6.90
	Totals	100.00	100.00



F 4c

Racemic sample

	Retention	Area %	Height %
	20.776	51.06	58.25
	27.052	48.94	41.75
	Totals	100.00	100.00
27.05 48.9 27.05 48.9	²⁰⁰ ¹⁰⁰ ² ²⁰⁰ ² ²⁰⁰ ²⁰	ioenriched sar	nple
			1
	Retention	Area %	Height %
_	Retention 20.488	Area % 96.57	Height % 96.19
	Retention 20.488 28.120	Area % 96.57 3.43	Height % 96.19 3.81
-	Retention 20.488 28.120 Totals	Area % 96.57 3.43 100.00	Height % 96.19 3.81 100.00